WHO advisory views conditions for use of Moderna's mRNA-1273 COVID-19 vaccine

26 January 2021

The World Health Organization’s Strategic Advisory Group of Experts on Immunization (SAGE) today issued interim recommendations for the use of the mRNA-1237 vaccine against COVID-19 developed by US biotech Moderna (NYSE: MRNA), whose shares were up more than 4% at $153.22 by late morning.

The UN health agency has so far only approved the Pfizer (NYE: PFE)/BioNTech (Nasdaq: BNTX) vaccine but it is expected to issue approval for the Moderna jab soon. Moderna’s vaccine – as does the Pfizer-BioNTech option - uses mRNA technology, and a decision from the WHO on this is expected shortly.

Summary of the recommendations

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK